Saturday, July 11, 2026

Drug profile · INN

dromostanolone propionate

dromostanolone propionate (DROLBAN) is a androgen receptor agonist. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — dromostanolone propionate
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

dromostanolone propionate (DROLBAN) is a androgen receptor agonist. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN dromostanolone propionate
Brand DROLBAN
Mechanism Androgen Receptor agonist
Target Androgen receptor
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Androgen Receptor agonist

Primary target: Androgen receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. bicalutamide Androgen Receptor antagonist
  2. danazol Progesterone receptor agonist
  3. nandrolone decanoate Androgen Receptor agonist
  4. testosterone Genito-urinary system and sex hormones (G03)
  5. testosterone cypionate Androgen Receptor agonist
  6. apalutamide Antineoplastic and immunomodulating agents (L02)

Frequently asked questions

What is dromostanolone propionate?

dromostanolone propionate (DROLBAN) is a androgen receptor agonist. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for dromostanolone propionate?

DROLBAN is a marketed brand name for dromostanolone propionate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of dromostanolone propionate?

dromostanolone propionate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.